Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,054
  • Shares Outstanding, K 33,203
  • Annual Sales, $ 10,430 K
  • Annual Income, $ -32,580 K
  • 60-Month Beta 2.53
  • Price/Sales 6.81
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.03 +5.42%
on 10/11/19
2.56 -16.37%
on 09/23/19
+0.03 (+1.42%)
since 09/18/19
3-Month
1.71 +25.15%
on 08/09/19
2.67 -19.84%
on 07/23/19
-0.12 (-5.31%)
since 07/18/19
52-Week
0.60 +256.67%
on 12/11/18
2.90 -26.21%
on 07/17/19
+0.05 (+2.39%)
since 10/18/18

Most Recent Stories

More News
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2019, the independent Compensation...

CRIS : 2.14 (unch)
Patients Turn to Assistance Programs for Aid in the Fight Against Chronic Diseases

With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Additionally, demand is expected to keep growing for currently effective treatments. Not...

CRIS : 2.14 (unch)
IMMU : 15.44 (-2.65%)
ZIOP : 3.94 (-0.38%)
ONPH : 0.0320 (-17.95%)
Curis to Present at Cantor Fitzgerald Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis,...

CRIS : 2.14 (unch)
Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief Financial...

CRIS : 2.14 (unch)
Curis Hires Industry Veterans to Lead Clinical Development and Regulatory Affairs

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of Reinhard von Roemeling, M.D., as...

CRIS : 2.14 (unch)
Curis: 2Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $7.2 million in its second quarter.

CRIS : 2.14 (unch)
Curis Reports Second Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended...

CRIS : 2.14 (unch)
Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter financial...

CRIS : 2.14 (unch)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2019, the independent Compensation...

CRIS : 2.14 (unch)
Curis: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $9.9 million in its first quarter.

CRIS : 2.14 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 2.20
1st Resistance Point 2.17
Last Price 2.14
1st Support Level 2.11
2nd Support Level 2.08

See More

52-Week High 2.90
Last Price 2.14
Fibonacci 61.8% 2.02
Fibonacci 50% 1.75
Fibonacci 38.2% 1.48
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar